AU2005318424B2 - Quaternary ammonium salts as M3 antagonists - Google Patents
Quaternary ammonium salts as M3 antagonists Download PDFInfo
- Publication number
- AU2005318424B2 AU2005318424B2 AU2005318424A AU2005318424A AU2005318424B2 AU 2005318424 B2 AU2005318424 B2 AU 2005318424B2 AU 2005318424 A AU2005318424 A AU 2005318424A AU 2005318424 A AU2005318424 A AU 2005318424A AU 2005318424 B2 AU2005318424 B2 AU 2005318424B2
- Authority
- AU
- Australia
- Prior art keywords
- methyl
- hydroxy
- pyrrolidinium
- acetoxymethyl
- phenyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/14—Antitussive agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/10—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms
- C07D211/14—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Rheumatology (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Cosmetics (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Hydrogenated Pyridines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0428418.8A GB0428418D0 (en) | 2004-12-24 | 2004-12-24 | Organic compounds |
| GB0428418.8 | 2004-12-24 | ||
| PCT/EP2005/013897 WO2006066929A1 (en) | 2004-12-24 | 2005-12-22 | Quaternary ammonium salts as m3 antagonists |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2005318424A1 AU2005318424A1 (en) | 2006-06-29 |
| AU2005318424B2 true AU2005318424B2 (en) | 2009-10-08 |
Family
ID=34130968
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2005318424A Ceased AU2005318424B2 (en) | 2004-12-24 | 2005-12-22 | Quaternary ammonium salts as M3 antagonists |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US8153669B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP1831208B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2008525359A (cg-RX-API-DMAC7.html) |
| KR (1) | KR101259654B1 (cg-RX-API-DMAC7.html) |
| CN (1) | CN101080405B (cg-RX-API-DMAC7.html) |
| AT (1) | ATE521606T1 (cg-RX-API-DMAC7.html) |
| AU (1) | AU2005318424B2 (cg-RX-API-DMAC7.html) |
| BR (1) | BRPI0519292A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2589133A1 (cg-RX-API-DMAC7.html) |
| ES (1) | ES2370832T3 (cg-RX-API-DMAC7.html) |
| GB (1) | GB0428418D0 (cg-RX-API-DMAC7.html) |
| MX (1) | MX2007007722A (cg-RX-API-DMAC7.html) |
| PL (1) | PL1831208T3 (cg-RX-API-DMAC7.html) |
| PT (1) | PT1831208E (cg-RX-API-DMAC7.html) |
| RU (1) | RU2394031C2 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2006066929A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0428416D0 (en) | 2004-12-24 | 2005-02-02 | Novartis Ag | Organic compounds |
| KR101495708B1 (ko) | 2007-02-23 | 2015-02-25 | 세라밴스 바이오파마 알앤디 아이피, 엘엘씨 | 무스카린 수용체 안타고니스트로 유용한 4차 암모늄 디페닐메틸 화합물 |
| MX2010002576A (es) | 2007-09-07 | 2010-04-01 | Theravance Inc | Compuestos que contienen guanidina, utiles como antagonistas de los receptores muscarinicos. |
| EP2222637A1 (en) | 2007-12-14 | 2010-09-01 | Theravance, Inc. | Amidine-containing compounds useful as muscarinic receptor antagonists |
| DE102008020746A1 (de) | 2008-04-25 | 2009-10-29 | Saltigo Gmbh | Verfahren zur Herstellung von quarternären Salzen von Piperidyl Estern der Mandelsäure |
| EP2935249B1 (en) | 2012-12-19 | 2018-12-12 | Novartis AG | Autotaxin inhibitors |
| JP6223543B2 (ja) | 2013-03-15 | 2017-11-01 | ボドール ラボラトリーズ, インコーポレイテッド | 多汗症の処置のための抗コリン作用性グリコピロレートエステル |
| US20160368873A1 (en) * | 2014-02-17 | 2016-12-22 | Ltt Bio-Pharma Co., Ltd. | Optically Active Form of Mepenzolate, and Ameliorating Agent for Chronic Obstructive Pulmonary Disease Which Contains Same as Active Ingredient |
| US20150259283A1 (en) | 2014-03-13 | 2015-09-17 | Brickell Biotech, Inc. | Formulation for soft anticholinergic analogs |
| EP3134398A1 (en) | 2014-04-24 | 2017-03-01 | Novartis Ag | Autotaxin inhibitors |
| US10472664B2 (en) | 2014-10-03 | 2019-11-12 | Institute For Cancer Research | Screening assay for identification of poly(ADP-ribose) polymerase 1 inhibitors |
| EP3200792A4 (en) | 2014-10-03 | 2018-05-09 | The Institute for Cancer Research d/b/a The Research Institute of Fox Chase Cancer Center | Poly (adp-ribose) polymerase 1 inhibitors structurally unrelated to nad |
| HK1253236A1 (zh) | 2015-07-21 | 2019-06-14 | 博多尔实验仪器公司 | 软性抗胆碱能药类似物的制剂 |
| TWI719046B (zh) | 2016-07-21 | 2021-02-21 | 美商波德實驗股份有限公司 | 軟性抗膽鹼類似物之製劑 |
| US11377422B2 (en) | 2019-03-11 | 2022-07-05 | Nocion Therapeutics, Inc. | Charged ion channel blockers and methods for use |
| CA3155568A1 (en) | 2019-11-06 | 2021-05-14 | Bridget Mccarthy Cole | Charged ion channel blockers and methods for use |
| US11332446B2 (en) * | 2020-03-11 | 2022-05-17 | Nocion Therapeutics, Inc. | Charged ion channel blockers and methods for use |
| US12162851B2 (en) | 2020-03-11 | 2024-12-10 | Nocion Therapeutics, Inc. | Charged ion channel blockers and methods for use |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0073645A2 (en) * | 1981-08-26 | 1983-03-09 | Dainippon Pharmaceutical Co., Ltd. | 2-Cyclic amino-2-(1,2-benzisoxazol-3-yl)acetic acid ester derivatives, process for the preparation thereof and composition containing the same |
| JPS58208270A (ja) * | 1982-05-28 | 1983-12-03 | Dainippon Pharmaceut Co Ltd | α−環状アミノフエニル酢酸エステル類並びにその酸付加塩類及び第4級アンモニウム塩類 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2746966A (en) * | 1953-11-02 | 1956-05-22 | Lakeside Lab Inc | Esters of bis-(nu-substituted-3-hydroxypiperidinium) alkanes |
| GB833820A (en) * | 1957-10-17 | 1960-04-27 | Beecham Res Lab | Improvements in or relating to the preparation of pyrrolidyl esters and quaternary compounds thereof |
| US2956062A (en) * | 1959-02-26 | 1960-10-11 | Robins Co Inc A H | Esters of amino alcohols |
| JPS6018661B2 (ja) | 1976-01-01 | 1985-05-11 | 太田製薬株式会社 | 1−(1,3−ジオキソラン−4−イルメチル)ピペリジノ−ル誘導体 |
| JPS5427570A (en) | 1977-07-30 | 1979-03-01 | Ota Pharma | Stereoisomer of 44acyloxyy11 alkyll11*1*33dioxolanee44 ylmethyl* pideridinium salt derivative |
| JPS5679688A (en) | 1979-12-04 | 1981-06-30 | Ota Seiyaku Kk | 4-acyloxy-1- 1,3-dioxoran-2-ylmethyl piperidine derivative and its production |
| GB9023023D0 (en) | 1990-10-23 | 1990-12-05 | Barlow Richard B | Pharmaceutical compositions |
| SI0937041T1 (en) | 1996-11-11 | 2003-10-31 | Christian R. Noe | Use of a pharmaceutically acceptable salt of (3R,2'R)-3-((Cyclopently-hydroxyphenylacetyl)oxy)-1,1-dimethyl-pyrrolidinium for the preparation of a medicament |
| EP1302458A4 (en) | 2000-07-11 | 2005-10-19 | Banyu Pharma Co Ltd | ESTERDERIVATE |
| ES2206021B1 (es) | 2002-04-16 | 2005-08-01 | Almirall Prodesfarma, S.A. | Nuevos derivados de pirrolidinio. |
| WO2004056767A1 (en) * | 2002-12-23 | 2004-07-08 | Ranbaxy Laboratories Limited | 1-substituted-3-pyrrolidine derivatives as muscarinic receptor antagonists |
| PE20050231A1 (es) * | 2003-06-24 | 2005-05-20 | Novartis Ag | Derivados de piperidinium y pirrolidinium como antagonistas del receptor muscarinico m3 |
| EP1781607A2 (en) * | 2004-08-19 | 2007-05-09 | Ranbaxy Laboratories Limited | Pyrrolidine derivatives as muscarinic receptor antagonists |
-
2004
- 2004-12-24 GB GBGB0428418.8A patent/GB0428418D0/en not_active Ceased
-
2005
- 2005-12-22 KR KR1020077014261A patent/KR101259654B1/ko not_active Expired - Fee Related
- 2005-12-22 PT PT05820639T patent/PT1831208E/pt unknown
- 2005-12-22 RU RU2007128085/04A patent/RU2394031C2/ru not_active IP Right Cessation
- 2005-12-22 WO PCT/EP2005/013897 patent/WO2006066929A1/en not_active Ceased
- 2005-12-22 CA CA002589133A patent/CA2589133A1/en not_active Abandoned
- 2005-12-22 JP JP2007547368A patent/JP2008525359A/ja active Pending
- 2005-12-22 ES ES05820639T patent/ES2370832T3/es not_active Expired - Lifetime
- 2005-12-22 US US11/721,989 patent/US8153669B2/en not_active Expired - Fee Related
- 2005-12-22 AU AU2005318424A patent/AU2005318424B2/en not_active Ceased
- 2005-12-22 MX MX2007007722A patent/MX2007007722A/es active IP Right Grant
- 2005-12-22 AT AT05820639T patent/ATE521606T1/de active
- 2005-12-22 EP EP05820639A patent/EP1831208B1/en not_active Expired - Lifetime
- 2005-12-22 BR BRPI0519292-7A patent/BRPI0519292A2/pt not_active IP Right Cessation
- 2005-12-22 PL PL05820639T patent/PL1831208T3/pl unknown
- 2005-12-22 CN CN2005800429764A patent/CN101080405B/zh not_active Expired - Fee Related
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0073645A2 (en) * | 1981-08-26 | 1983-03-09 | Dainippon Pharmaceutical Co., Ltd. | 2-Cyclic amino-2-(1,2-benzisoxazol-3-yl)acetic acid ester derivatives, process for the preparation thereof and composition containing the same |
| JPS58208270A (ja) * | 1982-05-28 | 1983-12-03 | Dainippon Pharmaceut Co Ltd | α−環状アミノフエニル酢酸エステル類並びにその酸付加塩類及び第4級アンモニウム塩類 |
Also Published As
| Publication number | Publication date |
|---|---|
| US8153669B2 (en) | 2012-04-10 |
| PL1831208T3 (pl) | 2012-01-31 |
| BRPI0519292A2 (pt) | 2009-01-06 |
| EP1831208B1 (en) | 2011-08-24 |
| RU2007128085A (ru) | 2009-01-27 |
| JP2008525359A (ja) | 2008-07-17 |
| EP1831208A1 (en) | 2007-09-12 |
| AU2005318424A1 (en) | 2006-06-29 |
| KR20070089953A (ko) | 2007-09-04 |
| ES2370832T3 (es) | 2011-12-23 |
| CN101080405B (zh) | 2011-05-11 |
| PT1831208E (pt) | 2011-10-31 |
| GB0428418D0 (en) | 2005-02-02 |
| HK1109767A1 (en) | 2008-06-20 |
| ATE521606T1 (de) | 2011-09-15 |
| CN101080405A (zh) | 2007-11-28 |
| MX2007007722A (es) | 2007-08-14 |
| US20090227590A1 (en) | 2009-09-10 |
| CA2589133A1 (en) | 2006-06-29 |
| KR101259654B1 (ko) | 2013-04-30 |
| WO2006066929A1 (en) | 2006-06-29 |
| RU2394031C2 (ru) | 2010-07-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US8084463B2 (en) | Quinuclidine derivatives and their use as muscarinic M3 receptor antagonists | |
| EP1831208B1 (en) | Quaternary ammonium salts as m3 antagonists | |
| US7947730B2 (en) | Piperidinium and pyrrolidinium derivatives as ligands for the muscarinic M3 receptor | |
| AU2005318423B2 (en) | Pyrrolinidium derivatives as M3 muscarinic receptors | |
| US20090311178A1 (en) | Pyrrolinidium derivatives as m3 muscarinic receptors | |
| HK1109767B (en) | Quaternary ammonium salts as m3 antagonists | |
| CN1805935B (zh) | 作为毒蕈碱m3受体配体的哌啶*和吡咯烷*衍生物 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FGA | Letters patent sealed or granted (standard patent) | ||
| MK14 | Patent ceased section 143(a) (annual fees not paid) or expired |